Dra. Anna Sureda
Head of the Onco-Hematology Service
Dr. Anna Sureda (MD, PhD) graduated in Medicine and Surgery from the Universidad Autónoma de Madrid in 1986, and completed her residency in Hematology and Hemotherapy at the Ramón y Cajal Hospital in Madrid in 1990. In January of 1991 she began working as a Hematology Consultant at the Clinical Hematology Unit of the Santa Creu i Sant Pau Hospital in Barcelona, where she was later appointed Head of Ambulatory Care in 2002.
In January of 2011 Dr. Sureda moved to Cambridge, UK, where she obtained a position as a Senior Consultant in Lymphomas and the Transplantation of Hematopoietic Progenitors. Two years later she returned to Barcelona, where she works as Head of the Onco-Hematology Section and Hematology Service at the Dexeus University Hospital. Dr. Sureda spent four-months at the University of Heidelberg, Germany, in 1990, and another four months at the Fred Hutchinson Cancer Research Center in Seattle (US) in 1993. She is currently the Head of the Clinical Hematology Service at the Institut Català d'Oncologia – Hospitalet de Llobregat in Barcelona.
Dr. Sureda has focused her scientific career on clinical research in the treatment of patients with Hodgkin's lymphoma, non-Hodgkin's lymphoma and multiple myeloma, evaluating new therapeutic strategies, including immunotherapy with the allogeneic transplantation of hematopoietic progenitors and targeted therapies. Over the course of her professional life she has participated in multiple Phase II and III clinical trials, either as a researcher or lead researcher. As a result of this clinical research, she has been certified as a Doctor of Medicine and Surgery, receiving cum laude honors for her work entitled "Autologous Transplantation of Hematopoietic Progenitors in Hodgkin's Lymphoma" in June of 2008.
Dr. Sureda has been an active member of the Spanish Lymphoma / Autologous Bone Marrow Transplant Group (GELTAMO) since 1993, and during her stay in the UK she was elected to serve as an active member of the NCRN Lymphoma Study Group. In April of 2004 she was elected Chair of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Since then, her main area of research interest is the analysis of results and prognostic factors related to the autologous and allogeneic transplantation of hematopoietic progenitors in patients with lymphoproliferative syndromes. After leaving her leadership position at the Lymphoma Working Party, Dr. Sureda was elected Secretary of the EBMT, a post she left in April of 2016. She was elected co-chair of the Lymphoma Committee of the Center for international Bone Marriw Transplantation Reserarch (CIBMTR) in January 2014.
Dr. Sureda has published more than 300 articles in internationally renowned journals and is a regular reviewer for Blood, Annals of Oncology, Bone Marrow Transplantation, The Hematology Journal, The European Journal of Hematology, and Annals of Hematology. She is an active member of the Spanish Society of Hematology and Hemotherapy, the Spanish Hematopoietic Transplantation Group, GELTAMO, EBMT, the European Hematology Association and the American Society of Hematology.Return